Medicis buys LipoSonix
This article was originally published in The Gray Sheet
Executive Summary
Privately held LipoSonix, which is developing a non-invasive, ultrasound technology-based system for body contouring as an alternative to invasive liposuction for fat reduction, is acquired by aesthetic dermal filler and pharmaceutical firm Medicis for $150 million on July 1. The deal calls for Medicis to pay up to an additional $150 million upon FDA approval of the technology "and if various commercial milestones are achieved on a worldwide basis," Medicis says. The firm anticipates FDA market go-ahead by 2011
You may also be interested in...
Solta Buys LipoSonix Noninvasive Fat Ablation Tech To Expand Aesthetics Biz
Aesthetics device firm Solta Medical is moving beyond skin aesthetics to the noninvasive fat-removal space with its acquisition of Medicis Pharmaceutical’s LipoSonix technology business unit.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.